Investment Pitches

Pitch Summary:
As parents of young children, we are constantly searching for screen-free ways to entertain our children. Enter Tonies. We can say from our own experience that their products are a godsend, working especially well at bedtime. Tonies sells audio-boxes and figurines. The figurines contain a chip that plays audio when placed on the box (mostly stories and songs related to the figurines). Tonies has the IP-licenses of most of the figures that kids are familiar with: Disney, Paw Patrol, Cars, Peppa Pig etc. The box is sold at no margin, instead the money is made on the figurines. At €15-20, it is a small purchase and works well as a gift. Typically, you can also buy additional stories in the app for existing figurines at €5-10 per story. This is easily done and - again from experience - an additional €5 to entertain your kids for an extra hour is money well spent. In essence the Toniebox is the razor and the Tonies are the razorblades. A typical buyer of a Toniebox acquires an additional -€200 on figurines and content. Given the large installed base of nearly 12m Tonieboxes sold, the extensive content library with many licensed Ips, large retail footprint and modest margin, competition is increasingly unlikely. Its nearest but much smaller competitor, Yoto, sells a differentiated player with audio cards, rather than figurines, which does not cater as well to younger kids. Tonies were introduced in 2016. Since then, the company has achieved an impressive penetration rate of over 50% in Germany with parents with young children. Tonieboxes are to be found also in many daycares. Despite its high penetration, Tonies has been able to grow at double-digit rates for three years in a row in the DACH region, mainly through more content. Last year the company grew 36% organically, of which an impressive 40% in its largest market, the US. Growth is mainly limited by what the organization can support. The CEO says continued growth around 30% is what it aims for. Currently they are only physically sold in the DACH region, the US, UK, Australia and New Zealand and France. Thus, Tonies has many years left to expand geographically. Additionally, it grows in content. This summer both Pokémon figurines and audio-based games for older children are launched, which is called Tonieplay. At its capital markets day in June, we expect to hear further expansion plans. This year it expects to grow above 20% revenue. Its EBITDA margin is reaching double digits for the first time. In the mature DACH region this margin is already above 25%, so over time other markets should trend towards this figure as the product mix moves towards more figurines and fewer Tonieboxes. It's a pretty unique investment case with both near-term triggers and excellent long-term prospects. Many investors dismiss it superficially as a fad or hype, but that perception is slowly changing. At 13x EV/EBITDA, with an in our view conservative EBITDA estimate, you get more than 30% earnings growth for the foreseeable future.

BSD Analysis:
Norbury Capital presents a compelling bull case for Tonies based on the razor-and-blade business model where audio boxes are sold at no margin while high-margin figurines drive profitability. The fund manager highlights the company's impressive market penetration of over 50% among German parents with young children and strong competitive moats through extensive IP licensing deals with Disney, Paw Patrol, and other popular children's brands. The investment thesis centers on significant geographic expansion opportunities, as Tonies currently operates in only six markets despite achieving 36% organic growth last year with 40% growth in the US market specifically. The company's margin expansion story is particularly attractive, with EBITDA margins reaching double digits for the first time while the mature DACH region already demonstrates 25%+ margins that other markets should eventually achieve. Management targets continued 30% growth rates, supported by new product launches including Pokémon figurines and Tonieplay for older children. At 13x EV/EBITDA, the fund manager views the valuation as attractive given expectations for over 30% earnings growth and believes market skepticism about the business being a fad creates an opportunity for patient investors.

Pitch Summary:
Ares Commercial Real Estate (ACRE) is a commercial mortgage REIT that has faced challenges with defaults but is now leveraging back up. The company reported distributable earnings of $0.12 in Q1 2026, close to covering its $0.15 dividend. ACRE is increasing its leverage, aiming for a target of 3.0x debt/equity, and has resolved some high-risk loans. The resolution of distressed properties could significantly boost earnings, and the company is positioned to benefit from a stabilizing market.

BSD Analysis:
ACRE's strategy to increase leverage while maintaining stable credit quality is a positive sign for future earnings growth. The resolution of high-risk loans and the potential sale of foreclosed properties could provide a substantial boost to distributable earnings. The company's focus on managing its portfolio and the improving market conditions suggest that ACRE is on the path to recovery. While risks of new defaults remain, the overall stability in the sector supports a bullish outlook for ACRE's valuation and dividend coverage.

Pitch Summary:
Medical Properties Trust, Inc. (MPT) is a REIT focused on hospital properties. The company has faced challenges with tenant bankruptcies, notably Steward Health Care, but is showing signs of recovery. MPT has entered a new lease with NOR Health Systems, expected to stabilize cash rent at $45 million annually. The company is also restructuring its UK operations to improve tax efficiency. Despite current dividend coverage issues, MPT is expected to cover its dividend soon as cash rent increases and refinancing efforts stabilize interest expenses.

BSD Analysis:
MPT's strategic moves, including the restructuring of its UK operations and new lease agreements, are set to enhance its financial stability. The anticipated increase in cash rent from NOR Health Systems and the re-tenanted hospitals will offset rising interest expenses. The company's significant cash reserves and potential proceeds from its DIP loan provide flexibility for debt reduction and share buybacks, which could further improve cash available for distribution. While challenges remain, MPT's upward trend suggests a positive outlook for dividend coverage and potential growth.

Pitch Summary:
Lockheed Martin is positioned to benefit from increased defense spending due to escalating geopolitical tensions. The company's robust backlog of $186.4 billion, with a significant portion expected to be recognized within the next year, underpins its revenue stability. The FY27 budget proposal, which includes substantial increases in funding for key programs like the F-35 and missile defense systems, signals strong future demand. Despite recent earnings misses, management's reaffirmation of full-year guidance suggests temporary setbacks rather than long-term issues. The stock's current valuation, trading below its fair value, presents an attractive entry point for investors.

BSD Analysis:
Lockheed Martin's reliance on US government contracts, which account for 70% of its sales, poses a risk, especially with potential shifts in budget priorities due to federal debt concerns. However, historical trends show defense appropriations often exceed initial requests, providing a buffer. The company's strategic expansion into international markets, with growing sales outside the US, mitigates some domestic budget risks. Additionally, Lockheed's investments in expanding production capacity for key defense systems align with anticipated demand increases. While competitive pressures from emerging players like SpaceX and Anduril Industries exist, Lockheed's established position and ongoing innovation efforts maintain its competitive edge.

Pitch Summary:
Nextpower Inc. has shown strong performance with a 48.75% price gain since the last Buy rating in October 2025. The company reported a 20% revenue increase in FY26 and a backlog exceeding $5.25 billion, indicating robust business quality. However, Q4 earnings showed a decline in revenue and EPS, and the stock's valuation appears full. With a forward PEG ratio 20.5% higher than the sector and limited EPS growth, the upside seems constrained. The stock is currently trading at a 32x FY27 adjusted EPS multiple, and while the EV/EBITDA valuation is more attractive, the free cash flow yield is low. The stock's reliance on policy-linked benefits and U.S. market concentration presents risks.

BSD Analysis:
Nextpower's strategic position in the growing solar industry is promising, with significant capacity additions expected in the coming years. However, the company's valuation is stretched, and the forward setup is more sensitive to valuation concerns. The FY27 guidance suggests a reinvestment phase with modest EBITDA growth, which may not justify the current premium valuation. Additionally, the company's free cash flow yield is thin, and the reliance on policy benefits could pose long-term risks. While the solar industry is poised for growth, Nextpower's current valuation does not offer a sufficient margin of safety for value investors. The stock is priced as a premium operator in a solar supercycle, but the risk-adjusted upside is limited.

Pitch Summary:
Federal Agricultural Mortgage Corporation (Farmer Mac) has demonstrated robust profitability despite recent pressures from elevated loan loss provisions. In Q1 2026, the company reported a net interest income increase of over 10% and a net profit jump of nearly 20%. The preferred dividends are well-covered, with a payout ratio of just over 12% of net income, indicating a favorable risk/reward ratio for preferred stock investors. The company's equity position remains strong, with common equity serving as a cushion against potential losses. Despite an uptick in non-accrual loans, the total amount of loans past due remains manageable. Farmer Mac's stock is trading at a reasonable valuation, with a price-to-book ratio of approximately 1.6 times and an earnings multiple of around 10-11 times anticipated net profit.

BSD Analysis:
Farmer Mac's ability to maintain profitability amidst rising interest rates and increased loan loss provisions highlights its resilient business model. The company's strategic focus on retaining earnings to expand its asset base supports its long-term growth prospects. The preferred stock offers an attractive yield, especially compared to the 5-year U.S. Treasury rate, making it a compelling investment for income-focused investors. The potential for capital gains if the preferred shares are called adds an additional layer of appeal. Overall, Farmer Mac's strong financial performance and prudent management of its equity and loan portfolios position it well for future success.

Pitch Summary:
MFA Financial is projected to deliver significant returns, with an estimated net gain of $716.89 based on dividends and target price estimates from analysts. The company's high beta indicates a higher risk, but also a potential for greater returns compared to the market. As a mortgage REIT, MFA Financial benefits from its focus on residential mortgage assets, providing a stable income stream through dividends. The company's strategy to capitalize on the housing market's dynamics positions it well for future growth.

BSD Analysis:
MFA Financial's focus on residential mortgage assets allows it to leverage the ongoing demand in the housing market. The company's ability to generate substantial dividend returns makes it an attractive option for income-seeking investors. However, the high beta suggests that investors should be prepared for volatility. The real estate sector's sensitivity to interest rate changes and economic conditions could impact MFA's performance. Nonetheless, the company's strategic asset management and focus on high-yield opportunities provide a robust foundation for potential growth.

Pitch Summary:
Sirius XM Holdings Inc. has demonstrated strong performance with a forward dividend yield of 4.18% and a positive return of 32.09% year-to-date. The company recently underwent a reverse stock split, which re-priced its shares, making it an attractive investment for dividend-focused investors. With a current price of $25.83, a $1,000 investment yields 37.71 shares, offering a return that exceeds the share price by 1.6 times. The company's ability to maintain positive returns and a robust dividend yield suggests a stable outlook.

BSD Analysis:
Sirius XM's strategic positioning in the media industry, particularly in satellite radio and streaming, provides it with a competitive edge. The company's spin-off from Liberty Media and its inclusion in the S&P 500 index highlight its market significance. Despite the challenges in the media sector, Sirius XM's consistent dividend payments and stock performance indicate resilience. The company's focus on maintaining a high dividend yield relative to its share price is a key factor in attracting income investors. However, the long-term sustainability of its business model, given the evolving media landscape, remains a consideration for potential investors.

Pitch Summary:
Hims & Hers Health, Inc. has returned to growth mode after a challenging period due to issues with GLP-1 drugs. Despite recent market disappointment, the company has outlined a robust growth trajectory with a target of $3 billion in sales for 2026. The transition to branded GLP-1 drugs, in partnership with Novo Nordisk, is expected to boost long-term growth and reduce investment risks. The company is also expanding into new specialties and international markets, further enhancing its growth potential. With the acquisition of Eucalyptus, Hims is poised to add significant revenue, making the current stock price an attractive entry point.

BSD Analysis:
Hims & Hers Health's strategic shift to branded GLP-1 drugs and its partnership with Novo Nordisk de-risk its business model and position it for sustained growth. The company's guidance for 27% revenue growth in Q2 and a 2026 revenue target of $3 billion highlight its strong growth prospects. The acquisition of Eucalyptus will further bolster its revenue base, potentially adding $450 million annually. Despite some margin pressure, the company's focus on scaling internationally and expanding into new health specialties like testosterone and menopause treatments will likely drive future profitability. The stock's current valuation, trading below 2x the 2027 sales forecast, presents a compelling investment opportunity given its growth trajectory.

Pitch Summary:
NVIDIA is expected to report its Q1 earnings with analysts projecting an EPS of $1.78 on $79.17 billion in revenue. The demand for GPUs remains strong, and the company's guidance will be crucial in determining the stock's reaction. Analyst Louis Gerard has a Strong Buy rating and is adding shares ahead of the report, anticipating a beat-and-raise scenario. However, he notes that the current stock price already reflects high expectations, and further upside requires a clean earnings beat. The focus will also be on hyperscaler spending and the ramp-up of Rubin.

BSD Analysis:
Despite the bullish sentiment, Tonga Capital holds a Sell rating, arguing that NVIDIA's projected profitability may not sustain hypergrowth at its current scale. They highlight the challenge of reconciling the need for reduced AI infrastructure costs with NVIDIA's cost structure. Additionally, Mott Capital points out that NVIDIA has been in an options squeeze since March, raising questions about whether the earnings results can overcome the built-in euphoria and event risk. Overall, while NVIDIA's growth prospects in AI and GPU demand are strong, the stock's high valuation and market expectations pose significant risks.

Pitch Summary:
NVIDIA Corporation is positioned to report another strong quarter, with expectations of surpassing its revenue forecast of $79.2 billion, driven by robust demand for its AI chips. Despite being overlooked in the AI chip race due to new IPOs and competitors, NVIDIA remains the clear leader in AI chip sales, particularly with its H100 equivalent chips. The company is expected to benefit from a potential return to selling high-end AI chips to China, which could significantly boost sales. NVIDIA's valuation at 27x forward EPS is attractive given its projected revenue growth of 80% and EPS growth of 120% in the current quarter. The stock's current price does not fully reflect the potential upside from these growth opportunities.

BSD Analysis:
NVIDIA's dominance in the AI chip market is underscored by its ability to consistently beat revenue estimates, with recent quarters showing significant earnings surprises. The company's strategic position is further strengthened by the increasing AI capex spending by major hyperscalers, which is expected to drive future demand for NVIDIA's chips. While the market has been distracted by competitors like AMD and Intel, NVIDIA's established customer base and technological leadership provide a competitive edge. The potential resumption of AI chip sales to China presents a substantial growth opportunity, although geopolitical risks remain a factor. Investors should consider NVIDIA's strong growth trajectory and market leadership when evaluating its investment potential.

Pitch Summary:
Perma-Fix Environmental Services, Inc. is poised for significant growth in the latter half of 2026 and into 2027, driven by multiple revenue streams from the Hanford nuclear waste site. The company is well-positioned to capitalize on a $4 billion contract for grouting, a critical process in nuclear waste management. Additionally, Perma-Fix is part of a consortium bidding for the decommissioning of the USS Enterprise aircraft carrier, presenting another substantial opportunity. The company's PFAS destruction business is gaining traction, with recent project completions and new facility developments. Despite a challenging Q1, the outlook for Perma-Fix is promising, with multiple projects expected to contribute to revenue growth.

BSD Analysis:
Perma-Fix's strategic positioning in the nuclear waste management sector, particularly at the Hanford site, underscores its potential for long-term growth. The company's involvement in high-value contracts, such as the USS Enterprise decommissioning, highlights its capability to handle complex projects. The expansion of its PFAS destruction facilities indicates a commitment to addressing emerging environmental challenges, which could open new revenue streams. While the recent financing round at $8.75 per share was a setback, the recovery in share price suggests investor confidence in future prospects. As the company continues to secure and execute large-scale projects, its financial performance is expected to improve significantly.

Pitch Summary:
Entravision's AdTech segment has become the dominant driver of the company's growth, with revenue increasing by 204% year-over-year in Q1 2026. This segment now accounts for 78% of total revenue and generated over $34 million in segment EBIT in a single quarter. The company's share price has reflected this positive performance, making Entravision the largest position in the portfolio. The focus is on understanding Smadex's business model, the programmatic advertising industry, and the growth potential if management continues to execute effectively.

BSD Analysis:
Entravision's transformation into a leader in the AdTech industry is evident from its impressive revenue growth and EBIT generation. The company's ability to capitalize on the programmatic advertising trend has positioned it well against its DSP peers. Continued diligence on Smadex's business model and the broader industry dynamics is crucial to assess the sustainability of this growth trajectory. The valuation of Entravision will depend significantly on management's execution and the ongoing expansion of the AdTech segment. Investors should monitor any fundamental changes in the business and industry to ensure the investment thesis remains intact.

Pitch Summary:
Ironwood Pharmaceuticals is rated as a Hold due to its potential for recovery despite recent negative stock performance. Linzess remains a market leader in the IBS-C and CIC segment, and Apraglutide offers future growth potential. The current share price of $3.67 reflects a market discount that investors can leverage. The company has a strong cash position and has shown positive cash flow generation. However, competition from Ardelyx and other players poses a challenge.

BSD Analysis:
Ironwood's financial performance has been impacted by Linzess's net-price drag, but the underlying volume continues to grow. The elimination of inflationary rebates has led to a significant increase in Linzess's net sales. The company's strategic focus on Apraglutide, with its potential $4B market, could provide substantial upside if clinical trials succeed. However, reliance on Linzess and the outcome of the STARS-2 trial for Apraglutide are key risks. The resignation of the CFO has been negatively perceived by the market, but it presents a buying opportunity for traders.

Pitch Summary:
The iShares MSCI Europe Financials ETF (EUFN) presents an attractive investment opportunity due to its valuation and potential growth drivers. EUFN holdings trade at a significant discount compared to the broader European equity universe and U.S. financials ETFs. The ETF is poised to benefit from higher interest rates in the short term, improved efficiency through digitalization and AI in the medium term, and the Capital Markets Union initiative in the long term. Despite the economic uncertainty and energy price volatility, EUFN's valuation at 11.6x trailing earnings remains compelling. The ETF's geographic exposure, primarily in the UK and Eurozone, aligns with central bank actions that could further support earnings growth. Investors should be aware of the currency risk and the ETF's high concentration in banks and insurance companies.

BSD Analysis:
EUFN's valuation at a 33% discount to the broader European market suggests room for appreciation, especially as the European economy is expected to experience slow but positive growth in 2026. Incremental rate hikes by central banks could enhance interest income, although this may be partially offset by weaker loan growth and higher credit costs. The ETF's focus on digitalization and AI could lead to increased efficiency, though competition from fintech startups poses a challenge. The Capital Markets Union initiative could provide long-term benefits by unifying trading standards and regulations across Europe. However, risks such as a potential recession, currency exposure, and regulatory changes should be considered. Overall, EUFN offers a favorable risk-reward profile for investors with a high-risk tolerance.